Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration

被引：0
|
作者：
Maruyama-Inoue, Maiko [1 ]
Chin, Jacob Yuhang [2 ]
Kadonosono, Kazuaki [1 ]
机构：
[1] Yokohama City Univ, Med Ctr, Dept Ophthalmol, 4-57 Urafune Cho,Minami Ku, Yokohama, Kanagawa 2320024, Japan
[2] Tan Tock Seng Hosp, Natl Healthcare Grp, Eye Inst, Singapore, Singapore
来源：
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | 2024年
关键词：
D O I：
10.1007/s00417-024-06516-8
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：3735 / 3736
页数：2
相关论文
共 50 条
  • [31] Clinical Outcomes of Intravitreal Brolucizumab Injection for Refractory Neovascular Age-related Macular Degeneration
    Lee, Jun Young
    Park, No Hae
    Kwon, Han Jo
    Park, Sung Who
    Byon, Ik Soo
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2024, 65 (09): : 596 - 604
  • [32] Neovascular Age-Related Macular Degeneration
    Veritti, Daniele
    Sarao, Valentina
    Lanzetta, Paolo
    OPHTHALMOLOGICA, 2012, 227 : 11 - 20
  • [33] Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
    Liberski, Slawomir
    Wichrowska, Malgorzata
    Kociecki, Jaroslaw
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (16)
  • [34] Full thickness macular hole after intravitreal brolucizumab injection in neovascular age-related macular degeneration
    Lee, Sang Hyeok
    Lee, Mee Yon
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2024,
  • [35] Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
    Justus G. Garweg
    Claudine A. Blum
    René-Pierre Copt
    Chiara M. Eandi
    Katja Hatz
    Christian F. Prünte
    Eleonora Seelig
    Gábor M. Somfai
    Ophthalmology and Therapy, 2023, 12 : 639 - 655
  • [36] Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
    Garweg, Justus G. G.
    Blum, Claudine A. A.
    Copt, Rene-Pierre
    Eandi, Chiara M. M.
    Hatz, Katja
    Pruente, Christian F. F.
    Seelig, Eleonora
    Somfai, Gabor M.
    OPHTHALMOLOGY AND THERAPY, 2023, 12 (02) : 639 - 655
  • [37] Short-term outcomes of intravitreal faricimab for refractory neovascular age-related macular degeneration
    Aljundi, Wissam
    Munteanu, Cristian
    Seitz, Berthold
    Abdin, Alaa Din
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2024, 262 (09) : 2867 - 2874
  • [38] One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment
    Takahashi, Hironori
    Inoda, Satoru
    Takahashi, Hidenori
    Takahashi, Ryota
    Hashimoto, Yuto
    Yoshida, Hana
    Kawashima, Hidetoshi
    Yanagi, Yasuo
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [39] Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration
    Khanani, Arshad M.
    Guymer, Robyn H.
    Basu, Karen
    Boston, Heather
    Heier, Jeffrey S.
    Korobelnik, Jean-Francois
    Kotecha, Aachal
    Lin, Hugh
    Silverman, David
    Swaminathan, Balakumar
    Willis, Jeffrey R.
    Yoon, Young Hee
    Quezada-Ruiz, Carlos
    OPHTHALMOLOGY SCIENCE, 2021, 1 (04):
  • [40] Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration
    Aldhanhani, Aisha A.
    Azzam, Ola A.
    AlAli, Sahar H.
    Almasri, Khaled G.
    Aljneibi, Shaikha H.
    Pichi, Francesco
    INTERNATIONAL OPHTHALMOLOGY, 2024, 44 (01)
12345